Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has regained compliance with the Nasdaq minimum bid price requirement. The company's shares maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.
September 19, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics has regained compliance with the Nasdaq minimum bid price requirement, which could potentially boost investor confidence.
Regaining compliance with Nasdaq's minimum bid price requirement is a positive development for Sonnet BioTherapeutics. It removes the risk of delisting, which could have negative implications for the stock. This news could potentially boost investor confidence and have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100